Belatacept in Kidney Transplantation of Moderately Sensitized Patients
Status:
Withdrawn
Trial end date:
2015-10-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of an immunosuppressive
medication, Belatacept, as a replacement for a calcineurin inhibitor, in combination with a
standard of care regimen of immunosuppressive medications and plasma exchange (plasmapheresis
and immunoglobulin treatment) for kidney transplant patients who are moderately sensitized
against their deceased donor and at-risk for delayed graft function. The hypothesis is that
moderately sensitized patients who receive Belatacept treatment with the standard of care
regimen will lead to lower acute rejection rates than historical controls based on assessment
of standard of care biopsies and standard Banff criteria.